IDiyas

For the Inventor, By the Inventor

San Carlos, CA, United States of America

Louise Robinson

USPTO Granted Patents = 14

Average Co-Inventor Count = 6.7

ph-index = 4

Forward Citations = 55(Granted Patents)


Company Filing History:

goldMedal11 out of 37 
 
Telik, Inc.
 patents
silverMedal3 out of 108 
 
Sanwa Kagaku Kenkyusho Co., Ltd.
 patents
bronzeMedal3 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 2003-2012

Loading Chart...
14 patents (USPTO):Explore Patents
1. 8129396 - 2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors (2012-03-06),
2. 8093231 - Sulfonylethyl phosphorodiamidates (2012-01-10),
3. 7297696 - Antagonists of MCP-1 function and methods of use thereof (2007-11-20),
4. 7262182 - Sulfonylethyl phosphorodiamidates (2007-08-28),
5. 7129215 - Tripeptide and tetrapeptide thioethers (2006-10-31),
6. 6998407 - Antagonists of MCP-1 function and methods of use thereof (2006-02-14),
7. 6992086 - Antagonists of MCP-1 function and methods of use thereof (2006-01-31),
8. 6962926 - Antagonist of MCP-1 function, and compositions and methods of use thereof (2005-11-08),
9. 6809113 - Antagonists of MCP-1 function and methods of use thereof (2004-10-26),
10. 6677365 - Antagonists of MCP-1 function and methods of use thereof (2004-01-13),
11. 6670364 - Antagonists of MCP-1 function and methods of use thereof (2003-12-30),
12. 6653321 - Naphthylsulfonic acids and related compounds as glucose uptake agonists (2003-11-25),
13. 6600069 - Benzene tricarboxylic acid derivatives as insulin receptor activators (2003-07-29),
14. 6525091 - Substituted diarylureas as stimulators for Fas-mediated apoptosis (2003-02-25),

Certainly! Here is the article about inventor Louise Robinson:

Title: The Inventive Journey of Louise Robinson: Pioneering Cancer Treatments through Innovations

Introduction:

Louise Robinson is a renowned inventor based in San Carlos, CA, known for her exceptional contributions in the field of cancer research and treatment. With 14 patents to her name, Louise has made significant strides in developing novel kinase inhibitors and pharmaceutical compounds aimed at combating cancer.

Latest Patents:

Louise's latest patents include 2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors. These compounds have shown promising results in the treatment of cancer, both independently and in combination with other therapies. Additionally, her work on sulfonylethyl phosphorodiamidates has opened up new possibilities for cancer treatment.

Career Highlights:

Having worked with esteemed companies like Telik, Inc. and Sanwa Kagaku Kenkyusho Co., Ltd., Louise Robinson has honed her expertise and played a pivotal role in translating innovative research into tangible solutions. Her patents reflect a deep commitment to advancing the field of oncology and improving patient outcomes.

Collaborations:

Throughout her career, Louise has collaborated with industry pioneers such as Hugo O Villar and Brian T Peterson. These collaborations have not only enriched her own work but have also fostered a culture of innovation and knowledge-sharing within the scientific community.

Conclusion:

In conclusion, Louise Robinson's dedication to pioneering cancer treatments through her innovative patents is truly commendable. Her relentless pursuit of scientific excellence and her impactful collaborations underscore her as a trailblazer in the field of oncology. We look forward to witnessing the continued impact of her inventions on the lives of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…